Home Cart Sign in  
Chemical Structure| 1820889-23-3 Chemical Structure| 1820889-23-3

Structure of INCB-057643
CAS No.: 1820889-23-3

Chemical Structure| 1820889-23-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

INCB057643 is an inhibitor of BET and it can reduce homologous recombination efficiency and augment PARP inhibitor activity in ovarian cancer.

Synonyms: INCB-057643

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of INCB-057643

CAS No. :1820889-23-3
Formula : C20H21N3O5S
M.W : 415.46
SMILES Code : O=C1C(C)(OC2=C(C=C(C=C2N1C)S(=O)(C)=O)C3=CN(C(C4=C3C=CN4)=O)C)C
Synonyms :
INCB-057643
MDL No. :MFCD31657400
InChI Key :VZSAMEOETVNDQH-UHFFFAOYSA-N
Pubchem ID :118467751

Safety of INCB-057643

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of INCB-057643

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02959437 Solid Tumors ... More >>Advanced Malignancies Metastatic Cancer Less << Phase 1 Phase 2 Active, not recruiting October 2021 United States, California ... More >> City of Hope National Medical Center Duarte, California, United States, 91010 University of California San Diego La Jolla, California, United States, 92093 United States, Illinois The University of Chicago Chicago, Illinois, United States, 60637 United States, Pennsylvania University of Pennsylvania Health System Philadelphia, Pennsylvania, United States, 19014 United States, Tennessee Sarah Cannon Nashville, Tennessee, United States, 37203 Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington University of Washington Seattle, Washington, United States, 98109 Spain Vall D Hebron Univ Barcelona, Spain, 08035 Univ De Navarra Pamplona, Spain, 31008 United Kingdom University College London Hospitals (Uclh) London, United Kingdom, W1t7ha Churchill Hospital Oxford, United Kingdom, Ox37le Less <<
NCT02711137 Solid Tumors Phase 1 Phase 2 Active, not recruiting December 2018 United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States, 35294-3300 United States, California University of California La Jolla, California, United States, 92093 United States, Colorado Sarah Cannon Research Institute at Health One Denver, Colorado, United States, 80218 United States, Connecticut Yale University New Haven, Connecticut, United States, 06510 United States, Florida Sylvester Comprehensive Cancer Center Miami, Florida, United States, 33136 Hematology - Oncology Associates of Treasure Coast Port Saint Lucie, Florida, United States, 34952 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington University Saint Louis, Missouri, United States, 63110 United States, New York University of Rochester, Wilmot Cancer Center Rochester, New York, United States, 14642 United States, North Carolina University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 Wake Forest Baptist Health Winston-Salem, North Carolina, United States, 27157 United States, Texas Oncology Consultants, P.A. Houston, Texas, United States, 77030 The Methodist Hospital Houston, Texas, United States, 77030 United States, Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 United States, Washington MultiCare Institute for Research and Innovation Tacoma, Washington, United States, 98405 Belgium Institut Jules Bordet, Clinical Trial Conduct Unit Brussels, Belgium, B-1000 France HÔPITAL SAINT-LOUIS, Service Hématologie Adultes Paris, France, 75010 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.03mL

2.41mL

1.20mL

24.07mL

4.81mL

2.41mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories